News

Read this week’s top infectious disease stories you may have missed, including Dr. Anthony Fauci’s announcement.

Everyone in this industry have experienced a profound sense of exhaustion, trauma, grief, fear, and frustration. Surgeon General Vivek Murthy, MD, continues to make this issue a priority with a recent article.

The European Commission approved lenacapavir to treat multidrug-resistant HIV infection. The long-acting HIV treatment regimen will be marketed as Sunlenca and available in injection or tablet form.

The companies are requesting the Emergency Use Authorization (EUA) for 30-µg booster dose of an Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine for individuals 12 years of age and older.

Guest author Seth Lederman, MD, calls Long COVID "one of the most pressing global health threats I have seen since fighting HIV/AIDS."

A third dose of mRNA COVID-19 vaccines may allow most immune compromised patients with hematologic cancers to achieve antibody response levels similar to those of healthy adults after a two-dose series.

WHO guidelines on HIV, hepatitis and STIs focus on populations with high risk of infections but low inclusion in prevention and treatment programs.

56% of adults with evidence of Omicron seropositivity did not know they were infected.

WHO issues new HCV treatment recommendations that include "radical simplification" of care pathways, in pursuit of testing and treatment goals.

Durable immune responses are seen in all age groups, even with significant discrepancies in antibody levels between children and adults.

CDC links 2021 outbreak of tuberculosis in US affecting 113 persons and causing at least 3 deaths to bone grafts from one infected, deceased donor.

Risk of severe maternal morbidity was highest during the period when Delta was the predominant COVID-19 variant.

The study was longitudinal in nature, comparing at-risk people who became infected with HIV to at-risk people who did not.

Home Run Inn Frozen Foods sausage pizzas have been recalled after consumers reported finding metal in the pizza.

If it is granted an Emergency Use Authorization (EUA), the vaccine could be used as a booster dose for individuals 18 years and older vaccinated with any of the other available COVID-19 vaccines.

Investigators sought to address the effectiveness of vaccination after COVID-19 recovery.

6 months after acute COVID-19 infection, patients had elevated usage of health care services to treat post-COVID conditions.

The booster is designed for immunization against the original wild strain as well as Omicron variant.

Neutralization of BA.4 and BA.5 dropped significantly for individuals who were infected with a previous strain of Omicron, even if they were also vaccinated.

Ongoing wastewater surveillance in San Diego seeks to track and predict monkeypox infection surges.

The FDA has approved Baloxavir Marboxil (Xofluza) for children 5 years and older to treat and prevent influenza.

Asymptomatic individuals in low-risk settings do not have to quarantine after COVID-19 exposure, CDC says.

Next generation antimalarial monoclonal antibody is three times more potent than predecessor in preventing parasitemia, stopping parasite replicating.

Langya virus, a new type of henipavirus, was identified in at least 35 people in eastern China. The virus is suspected to have infected shrews before jumping to humans.

The agency decided to allow for intradermal injection thus increasing the number of available doses substantially.

Expanding Medicaid and reducing stigma can bolster equitable HIV PrEP access, Dr. Patrick Sullivan says.

The company and its partner, Pfizer, are preparing for the potential launch of 2 variant-adapted bivalent COVID-19 vaccines assuming authorizations from FDA and EMA.

An FDA advisory committee will meet on September 22, 2022 to decide whether to approve a biologics license application (BLA) for Ferring’s recurrent C difficile biotherapeutic, RBX2660.

After widespread implementation of HIV pre-exposure prophylaxis (PrEP) among gay and bisexual men in Australia, population-level incidence of chlamydia and gonorrhea stabilized, allaying fears that PrEP would lead to a rise in STIs, a recent study found.

The latest MMWR offered guidance to these high-risk groups.